Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Duramed Cenestin And Pfizer Aricept In Pilot Study For Early Alzheimer's

  • News

Executive Summary

Duramed is planning clinical studies of its synthetic conjugated estrogen Cenestin in combination with Pfizer/Eisai's Aricept for treatment of early Alzheimer's disease, the company said during a Feb. 28 conference call.

You may also be interested in...



Wyeth Wants Premarin Petitions Excluded From Duramed Antitrust Suit

Wyeth-Ayerst's efforts to influence regulatory decisions about conjugated estrogens via citizens' petitions are an early focus of arguments in Duramed's antitrust suit against the company.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

Table

View full table

Tags:
Latest Headlines

Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings

China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’

Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116

Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length

See All
UsernamePublicRestriction

Register

PS037461

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By